Studies described above document that SAHA treatment attenuates cellular derangements induced by Abcd1 silencing in U87 astrocytes and B12 oligodendrocytes via induction of Abcd2/Abcd3 expression and that SAHA treatment may have therapeutic potential in X-ALD. The gene discussed is ABCD3; the disease is X-linked adrenoleukodystrophy.